M&A / Deals

Pharma’s M&A Train Is on Track for Record Highs With More Deals To Come: Analysts

BioSpace

After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M A action from other big names, including Novartis, Amgen and AbbVie.

M&A / Deals Read full story

pharminent April 3, 2026 (Last updated: April 3, 2026)

BioSpace

After a flurry of deals over the past week from Eli Lilly, Merck and Biogen, analysts predict more M A action from other big names, including Novartis, Amgen and AbbVie.

M&A / Deals Read full story

Related Stories

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

CordenPharma inks AmbioPharm buyout to continue peptide production expansion

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

You May Have Missed

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

ASCO26: In vivo oncology approaches continue to show promise